Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 25 versus MINIZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 25 versus MINIZIDE.
ALDORIL 25 vs MINIZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Prazosin is a selective alpha-1 adrenergic antagonist that inhibits vascular smooth muscle contraction, reducing peripheral vascular resistance and blood pressure. Polythiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing sodium and water excretion, and reducing intravascular volume.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
1-2 capsules orally twice daily; each capsule contains prazosin 0.5 mg and polythiazide 0.5 mg. Titrate based on blood pressure response.
None Documented
None Documented
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
2-3 hours (prazosin component); prolonged in heart failure or renal impairment
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Renal: 90% (unchanged drug and metabolites); biliary/fecal: <10%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination